Hypogonadism in Men: Causes, Symptoms, and Treatment

—————————————————————-

“Low T” is the marketing term. Hypogonadism is what clinicians actually mean — inadequate production of testosterone (and, often, impaired sperm production), with consequences that can range from infertility and reduced libido to bone loss and muscle atrophy. Understanding the distinction between primary hypogonadism (the testes themselves are not working) and secondary hypogonadism (the brain is not signaling them properly) matters because the workup, treatment, and prognosis differ for each. The Endocrine Society Clinical Practice Guideline on testosterone therapy and the AUA Testosterone Deficiency Guideline are the most authoritative US frameworks for diagnosis and management. This article is general education, not medical advice, and it is not a guide to self-diagnosis or self-treatment.

What Hypogonadism Is

Hypogonadism is the clinical syndrome of testosterone deficiency producing characteristic symptoms together with biochemical evidence of inadequate testicular function. Importantly, it is a diagnosis a clinician makes — not something you can confirm from a single at-home test or a symptom checklist. In practice, most US clinicians look for a total testosterone below roughly 300 ng/dL confirmed on repeat morning testing, accompanied by consistent symptoms. Different guidelines use slightly different thresholds: the AUA guideline uses a 300 ng/dL cutoff, while the Endocrine Society has used approximately 264 ng/dL based on a harmonized reference range. Reference ranges also vary by laboratory and assay, which is one reason interpretation belongs with a clinician rather than a spreadsheet.

The hypothalamic-pituitary-gonadal (HPG) axis explains the classification. The hypothalamus releases GnRH, which stimulates the pituitary to release LH and FSH. LH drives testicular Leydig cells to produce testosterone; FSH supports spermatogenesis. A breakdown anywhere along this axis can produce testosterone deficiency, and where the breakdown sits determines whether the condition is called primary or secondary.

Primary Hypogonadism (Hypergonadotropic)

Primary hypogonadism reflects testicular failure. The testes cannot produce adequate testosterone despite strong stimulation from the pituitary. Lab findings show low testosterone with elevated LH and FSH — the pituitary is shouting and getting no response.

Causes include Klinefelter syndrome (47,XXY, the most common genetic cause, affecting on the order of 1 in 600 to 1,000 males), bilateral orchiectomy, mumps orchitis, testicular trauma, undescended testes, chemotherapy and radiation toxicity, certain autoimmune disorders, and idiopathic testicular failure. Varicoceles and prior testicular torsion can contribute in some men. Men with Klinefelter syndrome often present in adolescence or early adulthood with delayed puberty, infertility, gynecomastia, or tall stature with disproportionate limb length, though presentations vary widely and diagnosis is frequently delayed.

Secondary Hypogonadism (Hypogonadotropic)

Secondary hypogonadism reflects pituitary or hypothalamic dysfunction. Lab findings show low testosterone with low or inappropriately normal LH and FSH — the testes may be capable of working, but they are not getting an adequate signal.

Causes include pituitary tumors (especially prolactinomas — see high prolactin in men), other pituitary lesions, Kallmann syndrome (congenital GnRH deficiency, often with an impaired sense of smell), head trauma, pituitary apoplexy, hemochromatosis (iron overload damaging the pituitary), opioid-induced suppression, anabolic-steroid use, and chronic glucocorticoid use. Functional hypogonadism — a common pattern in middle-aged men — is largely secondary and often at least partly reversible: obesity, type 2 diabetes, metabolic syndrome, untreated obstructive sleep apnea, and serious chronic illness all tend to suppress the HPG axis.

Symptoms

The symptom cluster is broadly similar regardless of cause. Sexual symptoms — reduced libido, erectile dysfunction, fewer morning erections, reduced ejaculate volume — are the most specific but are not proof of hypogonadism on their own, since they have many other causes. Other possible manifestations include fatigue, depressed mood, decreased exercise capacity, increased body fat, decreased lean mass, decreased bone mineral density, hot flashes, gynecomastia, and reduced concentration. Because these symptoms are nonspecific and overlap with many common conditions, they warrant evaluation rather than self-diagnosis.

Onset matters. Pre-pubertal hypogonadism can produce classic eunuchoid features — tall stature with disproportionate limb length, sparse facial hair, reduced muscle development, and incomplete voice change. Adult-onset hypogonadism is typically subtler, with gradual symptom progression and preserved skeletal proportions.

How Hypogonadism Is Diagnosed

Diagnosis follows a structured pathway that hinges on confirmed low morning testosterone on repeat testing plus consistent symptoms. A focused history covers sexual function, energy, mood, fertility goals, prior testicular issues, head trauma, medications, alcohol and opioid use, and any pubertal abnormalities. Physical exam assesses testicular size and consistency (reduced testicular volume can suggest dysfunction), body habitus, secondary sexual characteristics, and signs of pituitary disease such as visual-field changes and headaches.

Initial labs typically include two separate morning total testosterone measurements, usually drawn between about 7 and 10 a.m., because testosterone follows a daily rhythm and a single value can be misleading. A diagnosis generally should not rest on one low reading. Additional tests may include free testosterone if the total is borderline, SHBG, LH, FSH, prolactin, TSH, ferritin (for hemochromatosis), and a complete metabolic panel. If LH and FSH are low or inappropriately normal alongside low testosterone, MRI of the pituitary may be indicated. Karyotyping is recommended in men with primary hypogonadism and small testicular volume without an obvious cause, to evaluate for Klinefelter syndrome. Semen analysis is part of the workup when fertility is relevant. Your clinician decides which tests apply to your situation.

Treatment Options

Treatment depends on the cause, severity, fertility goals, and symptom burden, and it should be individualized and supervised by a clinician. For functional hypogonadism, the first-line approach is usually reversing the underlying contributors. Weight loss, treatment of sleep apnea, opioid tapering under medical supervision, and discontinuing anabolic steroids can restore testosterone in many men. Meaningful weight loss in men with obesity often raises testosterone measurably, though results vary from person to person.

For hypogonadism that is not reversible — such as Klinefelter syndrome, prior orchiectomy, congenital causes, or persistent secondary causes — testosterone replacement therapy (TRT) is a standard treatment when a clinician judges it appropriate. Options include injections, transdermal gels, pellets, oral, and nasal formulations, and the choice depends on patient preference, insurance coverage, and clinical factors. TRT is prescriber-supervised and requires ongoing monitoring, which typically includes repeat testosterone levels, hematocrit (to watch for a rise in red blood cell count), PSA and prostate assessment in appropriate patients, and blood pressure. Side effects and monitoring are covered in our TRT side effects guide. TRT is not a treatment for the normal decline of testosterone with aging, and it should not be started to chase “anti-aging” or performance goals.

For men with secondary hypogonadism who want to preserve fertility, gonadotropin therapy (hCG, with or without recombinant FSH) can restore testicular function and sperm production. Clomiphene citrate stimulates the pituitary to increase LH and FSH and can raise testosterone while maintaining fertility; it is sometimes used off-label as an alternative to TRT in younger men, at a clinician’s discretion. Aromatase inhibitors such as anastrozole are occasionally used in men with elevated estradiol or obesity-related hypogonadism, though the evidence base is more limited. None of these medications should be self-sourced or self-dosed.

The 2025 FDA Testosterone Labeling Change

In 2025 the FDA issued class-wide labeling changes for all testosterone products, following its review of the large TRAVERSE cardiovascular outcomes trial and required post-market blood-pressure studies. The agency removed the boxed warning language about an increased risk of major adverse cardiovascular events, concluding that the available evidence did not support that specific boxed warning. At the same time, it added a new warning that testosterone can increase blood pressure, which raises cardiovascular risk over time, and it kept a “limitation of use” note stating that testosterone products are not approved for treating age-related low testosterone (sometimes called “age-related hypogonadism”). In short, the update reframed rather than eliminated cardiovascular caution: blood pressure is now an explicit monitoring concern, and treating normal aging remains off-label. Because labeling and guidance continue to evolve, ask your prescriber how the current label applies to you.

When to See a Doctor

Persistent symptoms of low libido, erectile dysfunction, fatigue, or mood changes lasting more than a few months warrant evaluation by a clinician. Younger men (under 40) with these symptoms deserve a particularly thorough workup, since primary hypogonadism in this age group is unusual and may point to a genetic or otherwise treatable condition. Visual changes, severe headaches, or milk-like nipple discharge alongside symptoms of hypogonadism can suggest a pituitary tumor and need prompt evaluation. See an endocrinologist, urologist, or an experienced primary care clinician rather than relying on direct-to-consumer testosterone marketing.

Men with infertility should have hormonal testing as part of their reproductive workup. Adolescents with delayed puberty (for example, no testicular enlargement by around age 14) deserve early evaluation. For overlapping concerns, see the low testosterone guide, the andropause guide, and the broader medical conditions hub.

Frequently Asked Questions

What is the difference between hypogonadism and low testosterone?

Hypogonadism is the medical syndrome — biochemical testosterone deficiency confirmed on repeat morning testing plus relevant symptoms — driven by inadequate testicular function or inadequate pituitary signaling. “Low T” is the lay and marketing term for the same condition or, more loosely, for any symptom attributed to lower-than-optimal testosterone. The clinical bar for a hypogonadism diagnosis is biochemical confirmation plus characteristic symptoms, interpreted by a clinician.

Is hypogonadism reversible?

It depends on the cause. Functional hypogonadism (driven by obesity, sleep apnea, opioids, or anabolic steroids) is often at least partly reversible by addressing the underlying cause. Primary hypogonadism (such as Klinefelter syndrome, post-orchiectomy, or established testicular failure) is generally permanent. Secondary hypogonadism from a pituitary tumor may improve with treatment of the tumor, while congenital causes usually require lifelong therapy.

Can hypogonadism cause infertility?

It can. Testosterone deficiency often reflects impaired testicular function and reduced sperm production. Notably, the treatment for infertility differs from TRT: hCG, FSH, and clomiphene aim to preserve or restore fertility, whereas testosterone replacement usually suppresses sperm production. A reproductive urology or fertility evaluation matters for any man planning conception — do not start testosterone if fertility is a goal without discussing it first.

How is Klinefelter syndrome diagnosed?

Karyotyping is the definitive test, showing the 47,XXY chromosomal pattern. Diagnosis is often delayed because signs (small testes, infertility, gynecomastia, tall stature) can be subtle until adulthood. Men with small testicular volume, primary hypogonadism, or unexplained infertility should discuss a karyotype with their clinician.

Is testosterone therapy safe?

When prescribed and monitored appropriately for a genuine diagnosis, TRT is a well-established treatment, but it carries risks and requires ongoing monitoring of testosterone, hematocrit, PSA, and blood pressure. Following the 2025 FDA labeling update, the cardiovascular boxed warning was removed while a blood-pressure warning was added, and testosterone remains not approved for treating normal age-related decline. Safety is individual, so discuss your specific risks and monitoring plan with your prescriber.

The Bottom Line

Hypogonadism is a defined medical condition with clear diagnostic criteria, multiple causes, and effective treatments. Sorting out primary versus secondary, reversible versus permanent, and fertility-relevant versus not is the work of a urologist, endocrinologist, or experienced primary care clinician working from confirmed labs — not a single at-home test. The right diagnosis leads to the right treatment, which may be lifestyle correction, fertility-preserving pharmacotherapy, or carefully monitored testosterone replacement, but rarely a one-size-fits-all answer.

Sources

• Endocrine Society — Clinical Practice Guideline on testosterone therapy in men with hypogonadism (endocrine.org)
• American Urological Association (AUA) — Testosterone Deficiency Guideline (auanet.org)
• FDA — Class-wide labeling changes for testosterone products (2025); TRAVERSE trial review (fda.gov)
• MedlinePlus — Hypogonadism; Klinefelter syndrome (medlineplus.gov)
• Mayo Clinic — Male hypogonadism (mayoclinic.org)